Cargando…
Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study
BACKGROUND: Although aminoglycosides are routinely used in neonates, controversy exists regarding empiric dosing regimens. The objectives were to determine gentamicin pharmacokinetics in neonates, and develop initial mg/kg dosing recommendations that optimized target peak and trough concentration at...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729057/ https://www.ncbi.nlm.nih.gov/pubmed/31492162 http://dx.doi.org/10.1186/s12887-019-1676-3 |
_version_ | 1783449535572344832 |
---|---|
author | Bergenwall, Monique Walker, Sandra A. N. Elligsen, Marion Iaboni, Dolores C. Findlater, Carla Seto, Winnie Ng, Eugene |
author_facet | Bergenwall, Monique Walker, Sandra A. N. Elligsen, Marion Iaboni, Dolores C. Findlater, Carla Seto, Winnie Ng, Eugene |
author_sort | Bergenwall, Monique |
collection | PubMed |
description | BACKGROUND: Although aminoglycosides are routinely used in neonates, controversy exists regarding empiric dosing regimens. The objectives were to determine gentamicin pharmacokinetics in neonates, and develop initial mg/kg dosing recommendations that optimized target peak and trough concentration attainment for conventional and extended-interval dosing (EID) regimens. METHODS: Patient demographics and steady-state gentamicin concentration data were retrospectively collected for 60 neonates with no renal impairment admitted to a level III neonatal intensive care unit. Mean pharmacokinetics were calculated and multiple linear regression was performed to determine significant covariates of clearance (L/h) and volume of distribution (L). Classification and regression tree (CART) analysis identified breakpoints for significant covariates. Monte Carlo Simulation (MCS) was used to determine optimal dosing recommendations for each CART-identified sub-group. RESULTS: Gentamicin clearance and volume of distribution were significantly associated with weight at gentamicin initiation. CART-identified breakpoints for weight at gentamicin initiation were: ≤ 850 g, 851-1200 g, and > 1200 g. MCS identified that a conventional dose of gentamicin 3.5 mg/kg given every 48 h or an EID of 8-9 mg/kg administered every 72 h in neonates weighing ≤ 850 g, and every 24 and 48 h, respectively, in neonates weighing 851-1200 g, provided the best probability of attaining conventional (peak: 5-10 mg/L and trough: ≤ 2 mg/L) and EID targets (peak:12-20 mg/L, trough:≤ 0.5 mg/L). Insufficient sample size in the > 1200 g neonatal group precluded further investigation of this weight category. CONCLUSIONS: This study provides initial gentamicin dosing recommendations that optimize target attainment for conventional and EID regimens in neonates weighing ≤ 1200 g. Prospective validation and empiric dose optimization for neonates > 1200 g is needed. |
format | Online Article Text |
id | pubmed-6729057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67290572019-09-12 Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study Bergenwall, Monique Walker, Sandra A. N. Elligsen, Marion Iaboni, Dolores C. Findlater, Carla Seto, Winnie Ng, Eugene BMC Pediatr Research Article BACKGROUND: Although aminoglycosides are routinely used in neonates, controversy exists regarding empiric dosing regimens. The objectives were to determine gentamicin pharmacokinetics in neonates, and develop initial mg/kg dosing recommendations that optimized target peak and trough concentration attainment for conventional and extended-interval dosing (EID) regimens. METHODS: Patient demographics and steady-state gentamicin concentration data were retrospectively collected for 60 neonates with no renal impairment admitted to a level III neonatal intensive care unit. Mean pharmacokinetics were calculated and multiple linear regression was performed to determine significant covariates of clearance (L/h) and volume of distribution (L). Classification and regression tree (CART) analysis identified breakpoints for significant covariates. Monte Carlo Simulation (MCS) was used to determine optimal dosing recommendations for each CART-identified sub-group. RESULTS: Gentamicin clearance and volume of distribution were significantly associated with weight at gentamicin initiation. CART-identified breakpoints for weight at gentamicin initiation were: ≤ 850 g, 851-1200 g, and > 1200 g. MCS identified that a conventional dose of gentamicin 3.5 mg/kg given every 48 h or an EID of 8-9 mg/kg administered every 72 h in neonates weighing ≤ 850 g, and every 24 and 48 h, respectively, in neonates weighing 851-1200 g, provided the best probability of attaining conventional (peak: 5-10 mg/L and trough: ≤ 2 mg/L) and EID targets (peak:12-20 mg/L, trough:≤ 0.5 mg/L). Insufficient sample size in the > 1200 g neonatal group precluded further investigation of this weight category. CONCLUSIONS: This study provides initial gentamicin dosing recommendations that optimize target attainment for conventional and EID regimens in neonates weighing ≤ 1200 g. Prospective validation and empiric dose optimization for neonates > 1200 g is needed. BioMed Central 2019-09-06 /pmc/articles/PMC6729057/ /pubmed/31492162 http://dx.doi.org/10.1186/s12887-019-1676-3 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Bergenwall, Monique Walker, Sandra A. N. Elligsen, Marion Iaboni, Dolores C. Findlater, Carla Seto, Winnie Ng, Eugene Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study |
title | Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study |
title_full | Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study |
title_fullStr | Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study |
title_full_unstemmed | Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study |
title_short | Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study |
title_sort | optimizing gentamicin conventional and extended interval dosing in neonates using monte carlo simulation – a retrospective study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729057/ https://www.ncbi.nlm.nih.gov/pubmed/31492162 http://dx.doi.org/10.1186/s12887-019-1676-3 |
work_keys_str_mv | AT bergenwallmonique optimizinggentamicinconventionalandextendedintervaldosinginneonatesusingmontecarlosimulationaretrospectivestudy AT walkersandraan optimizinggentamicinconventionalandextendedintervaldosinginneonatesusingmontecarlosimulationaretrospectivestudy AT elligsenmarion optimizinggentamicinconventionalandextendedintervaldosinginneonatesusingmontecarlosimulationaretrospectivestudy AT iabonidoloresc optimizinggentamicinconventionalandextendedintervaldosinginneonatesusingmontecarlosimulationaretrospectivestudy AT findlatercarla optimizinggentamicinconventionalandextendedintervaldosinginneonatesusingmontecarlosimulationaretrospectivestudy AT setowinnie optimizinggentamicinconventionalandextendedintervaldosinginneonatesusingmontecarlosimulationaretrospectivestudy AT ngeugene optimizinggentamicinconventionalandextendedintervaldosinginneonatesusingmontecarlosimulationaretrospectivestudy |